1-(3-氯苯基)-2-甲基哌嗪 | 75348-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-氯苯基)-2-甲基哌嗪
• 中文别名: 胰增血糖素(swine),N-(氨基羰基)-(9CI)
• 英文名称: 1-(3-chlorophenyl)-2-methylpiperazine
• CAS: 75348-33-3
• 化学式: C₁₁H₁₅ClN₂
• 分子量: 210.706
• InChiKey: KPPRCTGPPHBIJY-UHFFFAOYSA-N

物化性质

• 沸点：
  340.3±27.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-氯苯基)-2-甲基哌嗪 在 镍 氢气 、 三乙胺 作用下， 以 乙醇 、 甲苯 为溶剂， 25.0 ℃ 、310.27 kPa 条件下， 生成 4-[4-(3-Chloro-phenyl)-3-methyl-piperazin-1-yl]-pyridin-3-ylamine
  参考文献：
  名称：

  Saxena, Anil K.; Arunamurthy, V.; Patnaik, G. K., Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1980, vol. 19, # 10, p. 873 - 878

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(3-chlorobenzamino)propanoic acid ethyl ester 在 盐酸 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 氨 、 sodium methylate 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 22.5h， 生成 1-(3-氯苯基)-2-甲基哌嗪
  参考文献：
  名称：

  Effect of Modifications of the Alkylpiperazine Moiety of Trazodone on 5HT_2A and α₁ Receptor Binding Affinity

  摘要：

  A series of triazolopyridine derivatives (compounds 2a-I) were synthesized in order to-explore the effect of modifications of the alkylpiperazine moiety of trazodone (fragment A) on binding affinity for 5HT(2A) and alpha(1) receptors. All of the synthesized compounds show a decrease of affinity for both 5HT(2A) and alpha(1) receptors, as compared to trazodone, with the exception of compounds 2b,c which bear a methyl group in an alpha position to the aliphatic nitrogen atom N-1. These compounds showed a decrease of affinity only for the alpha(1) receptor. The stereochemical influence of the piperazine moiety of compound 2c was also evaluated. Enantiomer (S)-2c showed the most significant differences between 5HT(2A) and alpha(1) receptor affinity (IC50 values) and among the corresponding functional properties (pA(2) values). Since (S)-2c cannot generate the metabolite 4-(3-chlorophenyl)piperazine this product was selected for further pharmacological studies.

  DOI：

  10.1021/jm970700n

文献信息

• MONOACYLGLYCEROL LIPASE INHIBITORS
  申请人：Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis

  公开号：EP3875452A1

  公开（公告）日：2021-09-08

  Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

  提供的是式(I)的化合物，或其药学上可接受的盐或溶剂： 还提供了包含式(I)化合物的组合物。这些化合物和组合物还可用作药物，例如用于治疗由单酰基甘油脂酶（MAGL）调节的疾病的药物。还提供了利用这些化合物和组合物来抑制单酰基甘油脂酶（MAGL）的用途。
• [EN] 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS<br/>[FR] DÉRIVÉS 5-[(PIPÉRAZINE-1-YL) -3-OXO-PROPYL]-IMIDAZOLIDINE -2,4-DIONE COMME INHIBITEURS D'ADAMTS POUR LE TRAITEMENT DE L'ARTHROSE
  申请人：GALAPAGOS NV

  公开号：WO2016102347A1

  公开（公告）日：2016-06-30

  The present invention discloses compounds according to Formula (I), wherein R, R2, R3a, R3b, and Cy are as defined herein. The present invention discloses compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same and methods for the prophylaxis and/or treatment of inflammatory conditions and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis.

  本发明公开了根据式(I)的化合物，其中R、R2、R3a、R3b和Cy如本文所定义。本发明公开了抑制ADAMTS的化合物、其制备方法、包含该化合物的药物组合物以及用于预防和/或治疗涉及软骨降解和/或软骨稳态破坏的炎症状况和/或疾病的方法。
• [EN] N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES<br/>[FR] DERIVES DE N-PHENYL-PIPERAZINE ET METHODES DE PROPHYLAXIE OU DE TRAITEMENT DE MALADIES ASSOCIEES AU RECEPTEUR 5HT2C
  申请人：ARENA PHARM INC

  公开号：WO2005016902A1

  公开（公告）日：2005-02-24

  The present invention relates to certain substituted N-phenyl-piperazine derivatives of Formula: (I) that are modulators of the 5HT2c receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT2c receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.

  本发明涉及某些Formula: (I)的取代N-苯基哌嗪衍生物，它们是5HT2c受体的调节剂。因此，本发明的化合物对于预防或治疗与5HT2c受体相关的疾病或紊乱，如肥胖症、阿尔茨海默病、勃起功能障碍及相关疾病，是有用的。
• N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
  申请人：Smith Brian

  公开号：US20070179155A1

  公开（公告）日：2007-08-02

  The present invention relates to certain substituted N-phenyl-piperazine derivatives of Formula: (I) that are modulators of the 5HT 2c receptor. Accordingly, compounds of the present invention are useful for the prophylaxis or treatment of 5HT 2c receptor associated diseases or disorders, such as, obesity, Alzheimer Disease, erectile dysfunction and related disorders.

  本发明涉及某些替代N-苯基哌嗪衍生物，其化学式为：(I)，它们是5HT2c受体的调节剂。因此，本发明的化合物对于预防或治疗与5HT2c受体相关的疾病或疾病，如肥胖症、阿尔茨海默病、勃起功能障碍和相关疾病是有用的。
• 5-[(piperazin-l-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis
  申请人：GALAPAGOS NV

  公开号：US10941117B2

  公开（公告）日：2021-03-09

  The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

  本发明公开了符合式 I 的化合物： 其中R1、R2、R3a、R3b和Cy如本文所定义。 本发明涉及抑制 ADAMTS 的化合物、其生产方法、包含本发明化合物的药物组合物以及使用本发明化合物进行治疗的方法，通过施用本发明化合物来预防和/或治疗炎症和/或涉及软骨降解和/或破坏软骨稳态的疾病。